The FDA Grand Rounds is an educational presentation that is webcast monthly to highlight cutting-edge research underway across the Agency and its impact on protecting and advancing public health. Each session features an FDA scientist presenting on a key public health challenge and how FDA is applying science to its regulatory activities. The 45-minute educational presentation is followed by questions from the audience. You can also view the presentation under Past Grand Rounds following the live webcast. #FDAGrandRounds.
Thursday, September 14, 2023
12:00 p.m. - 1:00 p.m. ET
About the Speaker
Michael Schmitt, Ph.D.
Principal Investigator and Lab Chief in the Laboratory of Respiratory and Special Pathogens, Division of Bacterial, Parasitic, and Allergenic Products (DBPAP)
Office of Vaccines Research & Review (OVRR)
Center for Biologics Evaluation and Research (CBER)
U.S. Food and Drug Administration (FDA)
Dr. Michael Schmitt is a Principal Investigator and Lab Chief in the Laboratory of Respiratory and Special Pathogens, Division of Bacterial, Parasitic, and Allergenic Products in the Office of Vaccines Research & Review.
Dr. Schmitt’s current research is involved in the identification of new vaccine candidates for the bacterial pathogen Corynebacterium diphtheriae; with a focus on surface factors that are required for the acquisition of host-iron sources.
Before joining CBER in 1995, Dr. Schmitt was a Postdoctoral Fellow in the Department of Microbiology at the Uniformed Services University of the Health Sciences in Bethesda, MD. He received his Ph.D. in Microbiology at The University of Texas at Austin.
Past Grand Rounds
- The Plasmid Puzzle: Finding Solutions in Salmonella
- FDA’s Global Substance Registration System (GSRS) Unique Ingredient Identifiers (UNIIs) uniquely define substances in FDA-regulated products
- Electron Microscopy, Still a Powerful Research Tool
- Identification of Persistent Organic Pollutants in Foods: Method Development and Automation
- Microphysiological Systems as Novel Disease Models and Drug Development Tools
- A Modular Approach for Enhanced Plasmid Subtyping and AMR Gene Profiling of Plasmids
- The Scientific Basis of Proposed Tobacco Product Standards to Prohibit Menthol as a Characterizing Flavor in Cigarettes and Flavors in Cigars
- Wastewater Surveillance for SARS-CoV-2 Variants: a pandemic response project leveraging FDA’s GenomeTrakr network
- Medical Extended Reality: Applications and Challenges
- Quality Considerations for the Multi-Attribute Method (MAM) for Therapeutic Proteins
- Polio Vaccines: Past, Present, and the Future
- One Health at FDA: From Concept to Application
- Some Perspectives on Data Science and Coronaviruses
- The Saga of Phosphatidylinositol 3-Kinase (PI3K) Inhibitors
- MinION Sequencing of Foodborne Pathogens
- An Overview of Tattoo Ink Research at the National Center for Toxicological Research
- Challenges in Predicting the Environmental Exposure Concentration of Terrestrial Animal Drugs
- Development and Testing of Warnings for Tobacco Products: Scientific and Regulatory Considerations
- Closer to Zero
- The Development of Cellular-Level Structural and Functional Biomarkers of Eye Disease Enabled by Adaptive Optics
- Laboratory and Clinical Studies to Investigate Whether Ranitidine Converts to a Probable Carcinogen in Humans